Sangamo BioSciences | SGMO - Stock


Sangamo BioSciences reported $0 in Stock for its fiscal quarter ending in March of 2022.





Stock Change Date
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Bayer EUR 11.97B 43M Jun/2026
BioCryst Pharmaceuticals USD 6.06M 71K Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Cipla INR 65.97B 4.37B Mar/2026
Clal Biotechnology ILS 4.44M 0 Mar/2021
CSL USD 6.47B 327M Jun/2025
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Grifols EUR 3.56B 63.19M Dec/2024
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
J&J USD 15.14B 561M Jun/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Merck USD 6.21B 272M Jun/2026
Novartis USD 6.22B 66M Jun/2026
Omeros USD 712K 266K Sep/2021
Pfizer USD 9.94B 722M Jun/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026